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Finger-Stick Glucose Monitoring
Issues of accuracy and speciﬁcity
S
ince its introduction three decades
ago, self-monitoring of blood glu-
cose (SMBG) using ﬁnger-stick
blood samples, test strips, and portable
meters has aided diabetes management,
principally by enabling patients—
particularly those treated with insu-
lin—to become full partners along with
health professionals in striving for excel-
lent glycemic control. Over time the use
of glucose meters has become easier and
faster with smaller and smaller blood
samplesyieldingresultsinamatterofsec-
onds. For this reason, glucose meters are
now increasingly used in hospital wards,
intensive care units, and other facilities
suchasdialysisunitsandinfusioncenters
to provide point-of-care results that
would take much longer through routine
laboratory channels. This technology has
largely taken the guess work out of diabe-
tes management. Without such technol-
ogy,intensiveglucosecontrolsuchasthat
achieved in the Diabetes Control and
Complications Trial may not have been
demonstrated to prevent or decrease mi-
crovascular complications; insulin pump
therapy would not really be practical; and
hypoglycemia would remain an even
greater source of anxiety for patients and
their families than it already is.
We have come to rely so much on
ﬁnger-stickglucosethatitiseasytoforget
its limitations. In considering this we will
discuss accuracy, speciﬁcity, and, in light
of those, inappropriate usage.
Accuracy
Although there is no universally binding
standard, guidelines issued by the Inter-
nationalOrganizationforStandardization
(ISO) are widely acknowledged. ISO
guideline 15197 suggests that for glucose
levels 75 mg/dl, a meter should read
within 15 mg/dl of the reference sample,
and for levels 75 mg/dl, the reading
should be within 20%. A meter also
should be able to meet these targets in at
least 95% of the samples tested (1).
Several examples serve to illustrate
the implications of this degree of impre-
cision. Assuming a meter does indeed
meet the ISO guideline, then a true glu-
cose level of 55 mg/dl could in fact yield
an SMBG reading of as low as 40 or as
highas70mg/dl,andoccasionally(1time
in 20) a reading beyond those limits.
While a reading of 40 mg/dl is likely to
prompt corrective action that could be
quite appropriate for a true value of 55
mg/dl,thesameisnotlikelytobethecase
for a reading of 70 mg/dl, which in many
instances will be regarded by the patient
as reassuring, if not cause for congratula-
tion. This could be particularly inappro-
priate—andhazardous—inapatientwith
hypoglycemia unawareness whose glu-
cose of 55 mg/dl is “on the way down”
rather than stable or increasing.
At the other end of the spectrum, a
true value of 350 mg/dl might register as
low as 280 or as high as 360 mg/dl. Be-
cause all of these values are obviously
much higher than desirable in any cir-
cumstance, it could be argued that this is
of no consequence because they all
should lead to glucose-lowering action.
But this is true only up to a point since in
these days of insulin infusion algorithms
aimed at achieving excellent glycemic
control in intensive care situations and
the use of premeal corrective insulin
doses in patients using multiple dose in-
sulinregimens,thedifferencesmentioned
could quite conceivably compromise the
success of those respective treatment
strategies. It has been suggested that in
critical care situations the error tolerance
limitforbedsideglucosetestingshouldbe
5 mg/dl (2).
Common experience tells us that the
majority of patients using meters for
SMBG are unaware of the magnitude of
thepotentialinaccuracyofresults,andwe
suspect that many health care providers
also tend to ascribe greater accuracy than
is warranted to portable glucose meter re-
sults. Comparison of results on the same
blood sample obtained by different
meters is instructive. One study found
that the degree of difference between
meter readings widened as the true glu-
cose concentration increased from 70 to
200 mg/dl, with differences ranging from
5.7 to 32% in more than half of the com-
parisons (3). Furthermore, the conver-
sion of whole blood glucose (measured
using ﬁnger-stick test strips) to the
plasma level reported by the devices will
vary depending on hematocrit, which is
typically lower and more variable in hos-
pitalized and intensive care patients than
in otherwise healthy outpatients (4). Po-
tential user errors such as applying insuf-
ﬁcient blood to the strip, using strips that
are out of date or exposed to excess mois-
ture or humidity, or failing to enter the
propercode(requiredforsomebutnotall
systems) can further compromise
accuracy.
Noneoftheseerrorsisreasonenough
for advising against the use of this tech-
nology, but we need to do a better job
educating patients and providers about
the limitations. As an aside, we believe
that ﬁnger stick self-monitoring of glu-
cosebypatientswhodonothavediabetes
but who believe they experience (usually
“reactive”) hypoglycemia is inappropriate
asameanstoestablishingadiagnosis.The
likelihood that low glucose levels, docu-
mented by self-monitoring in such pa-
tients, truly represent a pathological
degree of hypoglycemia is extremely
small, yet the practice of encouraging
such monitoring can help perpetuate
a false belief that a disorder of glucose
metabolism underlies the patient’s
symptoms.
Speciﬁcity
Enzymatic measurement of glucose con-
centration based on hexokinase is the
gold standard widely used in clinical lab-
oratories (5). Among the enzymes cur-
rently used in test-strip systems are
glucose oxidase, glucose dehydrogenase
nicotinamide adenine dinucleotide
(GDH-NAD), GDH ﬂavin adenine dinu-
cleotide (GDH-FAD), and GDH pyrrolo-
quinolinequinone (GDH-PQQ). Sensors
based on glucose oxidase are more sub-
strate-speciﬁc than those based on GDH,
but oxygen, being the recipient of elec-
trons from glucose oxidase, can nega-
tively affect the results from glucose
oxidase–based sensors (6). This is not a
problem with GDH-based systems, but
while GDH-FAD and GDH-NAD strips
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sugars other than glucose, the same is not
the case with GDH-PQQ, which is non-
speciﬁc. Maltose, galactose, and xylose
will be misinterpreted as glucose by
GDH-PQQ–based sensors (7). This cer-
tainly has clinical relevance in certain
situations.
The potential magnitude of error is
illustrated by a report from Australia (8).
A patient treated with intravenous immu-
noglobulin preparations containing mal-
tose was found to have capillary glucose
readings of 167 and 439 mg/dl using a
GDH-PQQ meter but simultaneous lab-
measuredvenousplasmaglucoselevelsof
41 and 187 mg/dl, respectively. On its
website, the U.S. Food and Drug Admin-
istration (FDA) draws attention to this
hazard by listing the following items as
being potential “interfering products”
withGDH-PQQstrips:Extraneal(icodex-
trin) peritoneal dialysis solution; some
immunoglobulins, including Octagam
5%, WinRho SDF Liquid, Vaccinia Im-
mune Globulin Intravenous (Human),
and HepaGamB; Orencia (abatacept);
Adept adhesion reduction solution (4%
icodextrin); and BEXXAR radioimmuno-
therapy agent (9). Additionally, the FDA
warns that any product containing or me-
tabolized into maltose, galactose, or xy-
lose could be a potential hazard in this
respect.
While it is likely that most Diabetes
Care readers will not personally have en-
countered problems relating to GDH-
PQQ strips, the article by Frias et al. (10)
in this issue illustrates that the possibility
of harm is not merely theoretical. In re-
viewingtheFDA’sManufacturerandUser
Facility Device Experience (MAUDE) da-
tabase (http://www.fda.gov/cdrh/MAUDE.
html) and the medical literature, the au-
thors identiﬁed 82 reported incidents with
death occurring in 20%. The method of re-
portingtoMAUDEprecludesdirectattribu-
tion of cause and effect in the cases where
death ensued, but it seems almost inescap-
able that inappropriate insulin treatment
leading to severe and unexpected hypogly-
cemia was a—or perhaps the—crucial fac-
tor. Almost 80% of the instances involved
peritonealdialysisusingicodextrin.Theau-
thorsdeclareaninterestinthattheyareem-
ployees of LifeScan, a Johnson & Johnson
Companythatmanufacturesandsellsmon-
itoring systems based on glucose oxidase
strips,but,inouropinion,thisdoesnotne-
gate the import of their report.
A table listing the strips that use
GDH-PQQ is displayed on the FDA web-
site (9). Accu-Chek (Roche Diagnostics)
and FreeStyle (Abbott Diabetes Care) are
the most commonly used. To be fair, the
manufacturers of these strips have issued
warnings about the interfering sugars.
The FDA advises to “avoid using GDH-
PQQ glucose test strips in healthcare fa-
cilities” and cautions that if they are used
“NEVERusethemonpatients. . .whoare
receiving interfering products” (9). De-
spitethis,seriousadverseeventscontinue
to be reported. A possible technical solu-
tion to the problem is the use of mutant
formsofGDH-PQQinvolvingaminoacid
substitution, which have good enzymatic
activity for glucose but reduced reactivity
for other sugars (5).
We would favor the FDA withdraw-
ing approval for use of GDH-PQQ strips
(other than mutant GDH-PQQ)—rather
thansimplyadvisingagainsttheiruse—in
situations speciﬁcally recognized as being
problematical, such as icodextrin perito-
neal dialysis or when maltose-containing
immune globulin is used, and setting a
date for the elimination of their use in
health care facilities in general.
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